Alan Garber Biography and Net Worth

Director of Exelixis

Alan M. Garber, M.D., Ph.D., has been appointed to the company's Board of Directors. Dr. Garber is the Henry J. Kaiser Jr. Professor and a Professor of Medicine at Stanford University, where he is also Professor of Economics, Professor of Health Research and Policy, and Professor of Economics in the Graduate School of Business (courtesy). He is the founding director of both the university's Center for Health Policy and the Center for Primary Care and Outcomes Research at the School of Medicine. He is a Staff Physician at the Veterans Affairs Palo Alto Health Care System, Associate Director of the VA Center for Health Care Evaluation, and Research Associate and Director of the Health Care Program of the National Bureau of Economic Research (NBER).

After graduating from Harvard College summa cum laude, Dr. Garber received his Ph.D. in economics from Harvard and an M.D. with research honors from Stanford, and completed his residency in Medicine at Brigham and Women's Hospital. He is the recipient of numerous honors and awards including the Young Investigator Award of the Association for Health Services Research (now AcademyHealth) and the Henry J. Kaiser Family Foundation Faculty Scholarship in General Internal Medicine. He has served as a consultant to the Institute of Medicine, the Congressional Office of Technology Assessment, the Clinical Efficacy Assessment Project of the American College of Physicians and as Chair of the Medical and Surgical Procedures Panel of the Medicare Coverage Advisory Committee (Center for Medicare and Medicaid Services). He is a member of the national Blue Cross and Blue Shield Association Medical Advisory Panel, the American Society for Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, and the National Advisory Council on Aging (National Institutes of Health).

What is Alan M. Garber's net worth?: The estimated net worth of Alan M. Garber is at least $1.19 million as of March 21st, 2024. Mr. Garber owns 35,703 shares of Exelixis stock worth more than $1,188,553 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Garber may own. Learn More about Alan M. Garber's net worth.
How do I contact Alan M. Garber?: The corporate mailing address for Mr. Garber and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Alan M. Garber's contact information.
Has Alan M. Garber been buying or selling shares of Exelixis?: Alan M. Garber has not been actively trading shares of Exelixis during the last quarter. Most recently, Alan M. Garber sold 19,205 shares of the business's stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $24.01, for a transaction totalling $461,112.05. Following the completion of the sale, the director now directly owns 35,703 shares of the company's stock, valued at $857,229.03. Learn More on Alan M. Garber's trading history.
Who are Exelixis' active insiders?: Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Maria Freire (Director), Maria Freire (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.
Are insiders buying or selling shares of Exelixis?: In the last year, Exelixis insiders bought shares 3 times. They purchased a total of 615,000 shares worth more than $12,668,000.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 739,715 shares worth more than $21,619,607.83. The most recent insider tranaction occured on November, 29th when EVP Jeffrey Hessekiel sold 60,000 shares worth more than $2,200,200.00. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.
Information on this page was last updated on 11/29/2024.

Alan M. Garber Insider Trading History at Exelixis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/21/2024	Sell	19,205	$24.01	$461,112.05	35,703
2/21/2023	Sell	40,000	$17.49	$699,600.00	31,417
3/1/2022	Sell	21,301	$21.00	$447,321.00
3/15/2021	Sell	40,000	$23.60	$944,000.00	52,718
2/14/2020	Sell	12,500	$21.02	$262,750.00	48,829
1/7/2020	Sell	86,956	$18.01	$1,566,077.56	91,329
4/1/2019	Sell	30,000	$23.99	$719,700.00	76,329
1/8/2019	Sell	11,250	$23.00	$258,750.00	72,579
4/16/2018	Sell	15,000	$20.25	$303,750.00	76,329
1/9/2018	Sell	15,000	$30.30	$454,500.00	64,829
12/9/2016	Sell	7,832	$16.90	$132,360.80

Alan M. Garber Buying and Selling Activity at Exelixis

Exelixis Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Today's Range

Now: $33.29

$33.11

$33.68

50 Day Range

MA: $33.51

$26.24

$36.46

2 Week Range

Now: $33.29

$19.20

$36.97

Volume

7,648,822 shs

Average Volume

2,082,318 shs

Market Capitalization

$9.51 billion

P/E Ratio

21.34

Dividend Yield

N/A

Beta

0.52

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.